List of All Articles with Tag 'm'

President Joe Biden intends to appoint Dr. Mandy Cohen to lead the US Centers for Disease Control and Prevention, the White House confirmed exclusively to CNN, succeeding Dr. Rochelle Walensky in the critical public health role as the agency grapples with challenges in the aftermath of the pandemic.

Friday's Liverpool transfer rumours include updates on Khephren Thuram, Micky van de Ven, Gabri Veiga, Fabio Carvalho & more.

PARIS Tesla's market value is essentially based on vehicle 'autonomy', said Tesla CEO Elon Musk on Friday, and

DOJ's report found that "systemic problems" at the city's police department led to George Floyd's murder in May 2020.

Former Google CEO Eric Schmidt bought the Alfa Nero superyacht that was ditched in Antigua in March 2022

Looking at the form of Major League Soccer teams in home and away games so far in 2023.

Memphis Grizzlies star Ja Morant has been suspended for 25 games without pay by the NBA for "conduct detrimental to the league," the NBA announced Friday.

Three years after George Floyd was murdered by then-Minneapolis police officer Derek Chauvin, the Justice Department issued a blistering report Friday of the city's police department, detailing racial discrimination, excessive and unlawful use of force, First Amendment violations and a lack of accountability for officers.

Micron Technology Inc. warned that about half of its sales tied to China-headquartered clients may be affected by

One of the scientists whose work pioneered the development of medications such as Ozempic and Wegovy has revealed why life may become “so miserably boring” after two years of using the drug. Ozempic is an FDA-approved medication used for the treatment of type 2 diabetes. It works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates blood sugar levels and slows down the rate at which food leaves the stomach, often creating the feeling of fullness. These semaglutide injections – sold under the brand names Ozempic and Wegovy – have soared in popularity as many people, including Hollywood celebrities, have used it for weight loss. What’s more, people have also found Ozempic has been effective in curing their addictive habits, like drinking, smoking, shopping, or nail biting. However, because of Ozempic’s increasing popularity, it has led to national shortages of the type 2 diabetes treatment – leaving those who actually need it without. In an interview with Wired, professor Jens Juul Holst – who received the Warren Alpert Foundation Prize in 2021 for his work developing treatments based on the GLP-1 hormone – spoke about the effects of Ozempic, and why he believes many people will stop taking the medication after just a few years. “What happens is that you lose your appetite and also the pleasure of eating, and so I think there’s a price to be paid when you do that,” Holst told Wired. “If you like food, then that pleasure is gone. The craving for food for some people is taken away when they take GLP-1 drugs.” He continued: “That may eventually be a problem, that once you’ve been on this for a year or two, life is so miserably boring that you can’t stand it any longer and you have to go back to your old life.” Holst added that medications like Ozempic and Wegovy have been on the market since 2005, though studies show that these people don’t stay on them for very long. “It’s just like every other drug, they don’t stay on it for many reasons,” he explained. “One of the reasons, as I said, is that once you have tried it and you realise you’ve lost interest in food, then that may be enough.” “We don’t know why people stop taking these drugs, but we know for a fact that they do stop. They do that all over the world.” A 2020 study found that 70 per cent of people who took GLP-1 drugs for type 2 diabetes stopped taking them within two years. However, this could pose a problem for many patients taking semaglutide injections. Research has found that people who stopped taking Ozempic or Wegovy for weight loss experienced weight rebound. A trial published in April 2022 saw participants gain back two thirds of the weight they had lost after 68 weeks of taking semaglutide. As for celebrities who use the once-weekly injection for weight loss, despite not having diabetes or clinical obesity, Hans instead called attention to the “many terrible problems” that those with diabetes have struggled with by not having drugs like Ozempic readily available. “Have you ever visited a diabetes hospital? It’s really deplorable,” he said. “People come in with amputated limbs and compromised cognitive functions and heart problems or they can barely move – they’re miserable and depressed. It’s really serious. There is so much you can improve with a drug that is not only a weight-loss drug but is also an anti-diabetic.” Amidst the popularity of semaglutide injections, the US Food and Drug Administration has issued warnings for consumers not to use off-brand versions of Ozempic or Wegovy, because they may not include the same GLP-1 hormone used in approved medications. Earlier this month, agency officials reported problems with patients using compounded versions of semaglutide – which combines traditional semaglutide with other ingredients. These drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs. Consumers should only use drugs containing semaglutide with a prescription from a licensed health care provider and obtained from a state-licensed pharmacy or other facilities registered with the FDA, the agency said. Read More What is ‘Ozempic face’? Doctors warn about facial ageing side effect of diabetes medications How does Wegovy work? The ‘game changing’ weight loss drug beloved by Hollywood FDA warns against using off-brand versions of Ozempic, Wegovy for weight loss Pregnant Stassi Schroeder admits she wants to ‘try’ Ozempic after giving birth Doctors warn about ‘Ozempic face’ side effect of medications Amy Schumer says she stopped taking Ozempic because of side-effects

A group of investors holding more than €1 billion ($1.09 billion) of SBB bonds have hired an adviser

NATO Secretary-General Jens Stoltenberg seems increasingly likely to have his term at the helm of the world’s biggest security organization extended yet again, as members struggle to agree on another candidate to replace him. Stoltenberg, a former Norwegian prime minister, has been NATO’s top civilian official since 2014. His term was due to expire last year but was extended for a second time to keep a steady hand at the helm after Russia’s full-scale invasion of Ukraine in February 2022. President Joe Biden and his NATO counterparts are due to choose a successor when they meet for a summit in Vilnius, Lithuania, on July 11-12. No candidate has been proposed publicly, and leaders usually decide by consensus on who should be appointed. Stoltenberg held talks with Biden in Washington on Tuesday. According to a U.S. official familiar with the leaders’ conversations, Biden made clear that he thinks highly of some the possible candidates whose names have been privately floated to succeed him. The official said, however, Biden conveyed to the NATO secretary-general that it’s “becoming increasingly evident that there’s not going to be consensus” among NATO allies on picking a new leader, said the official, who spoke on condition of anonymity to discuss the private conversation. Biden made it clear to Stoltenberg that he would welcome him sticking around longer — particularly with no end in sight to the war in Ukraine and challenges to get Sweden approved as a member of the 31-nation alliance. “The president thinks Stoltenberg has done a remarkable job over the past year and a half leading the alliance during Russia’s invasion,” the official said. “He’s also quite comfortable with Stoltenberg hanging on. He thinks he’s been a very effective leader.” The official stopped short of saying that Biden asked Stoltenberg outright to stay on as NATO chief. Asked repeatedly Friday about his future at the helm, Stoltenberg said: “I have nothing more to say about this. I have stated again and again that I don’t seek an extension. I have no other plans than to end my work here, when my tenure ends this fall.” The U.S. official also said that Biden had spoken highly of Danish Prime Minister Mette Frederiksen. NATO is keen to name a woman to the top post, and Denmark’s prime minister was thought to be a favorite after a meeting with Biden earlier this month. But in a televised interview on Thursday, Frederiksen said: “No, I am not on my way to NATO.” She did say that she would back Stoltenberg if he was willing to extend his mandate. German Defense Minister Boris Pistorius also made clear that he would back an extension for Stoltenberg if that became necessary. “If we don’t agree on a candidate for successor, NATO won’t be able to go without a secretary-general, and of course I am for an extension — particularly as I appreciate our cooperation,” he told reporters. Norwegian media said Friday that Biden has encouraged Stoltenberg to stay on. Norwegian public broadcaster NRK said it “had learned” that Biden’s message to Stoltenberg “was not to be misunderstood: Jens Stoltenberg must remain as Secretary General of NATO for a while longer.” The president of the European Commission, Ursula von der Leyen, has also ruled out her candidacy. Other possible names that were floated are Dutch Prime Minister Mark Rutte and U.K. Defense Secretary Ben Wallace. ___ Madhani reported from Washington. Associated Press writers Jan M. Olsen in Copenhagen, Denmark. and Geir Moulson in Berlin contributed to this report. Read More Ukraine war’s heaviest fight rages in east - follow live Charity boss speaks out over ‘traumatic’ encounter with royal aide NATO moves to protect undersea pipelines, cables as concern mounts over Russian sabotage threat How significant is the reported recapture of the first Ukrainian villages? Support mounts for Stoltenberg to stay on in NATO's top job